A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2001 After a Single Subcutaneous Injection in Healthy Subjects
Latest Information Update: 16 Aug 2023
At a glance
- Drugs SHR 2001 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Guangdong Hengrui Pharmaceutical
Most Recent Events
- 07 Aug 2023 Planned number of patients changed from 52 to 49.
- 07 Aug 2023 Status changed from not yet recruiting to recruiting.
- 14 Jul 2023 New trial record